Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

ICON Is Collaborating with Practice Fusion, Inc. to Advance Health Research

Share:

ICON plc, (NASDAQ:ICLR) a global provider of drug development
services to the pharmaceutical, biotechnology and medical device
industries, today announced that it is working with Practice
Fusion
to leverage active patient data in support of health research.

Practice Fusion, Inc., an Allscripts company, is an industry leading
cloud-based ambulatory electronic health record (EHR) platform in the
US, supporting more than 20,000 medical practices to deliver better care
to over five million patients monthly. Practice Fusion offers
connectivity solutions and services that can help make healthcare
management better for everyone—including clinical labs, pharmacies,
imaging centres, health systems and other US healthcare ecosystem
stakeholders. These connected partners utilize the Practice Fusion
platform to help coordinate care, and help develop innovative programs
to improve outcomes, reduce costs and enhance the patient experience.

"The collaboration between ICON and Practice Fusion explores innovative
uses of data collected directly through the Practice Fusion platform to
facilitate health research. Focus areas for potential collaboration
include: the ability to rapidly develop ‘Real-world' Registries; the use
of the EHR platform to streamline data collection for late phase studies
and post-market research programs; as well as the real time
identification of ‘active' patients for engagement in health research
programs", commented Ramita Tandon, EVP ICON Commercialization and
Outcomes.

Working with "Real" patient data, connected healthcare providers, and
data collected directly through an EHR system represents an order of
magnitude improvement over second-hand sources that the FDA has cited as
filled with discrepancies and which is not timely.

The relationship with Practice Fusion is another example of ICON's
leadership in applying targeted technology to help customers reduce the
time and cost of their development programs through more accurate
patient identification, research though real-world patient records and
faster patient recruitment.

"The use of EHR systems offers a significant differentiator of
second-hand data resources for more efficient retrospective and hybrid
studies in addition to selection of sites and patient recruitment"
continued Ramita Tandon, EVP ICON Commercialization and Outcomes.

"Working with ICON will enable Practice Fusion network physicians to
potentially improve the quality and value of patient care by
accelerating research and actively contributing to Real-World Evidence
which may be critical for developing novel treatments and communicating
treatment value", said Tom Langan, CEO, Payer & Life Sciences,
Allscripts.

About ICON plc
ICON plc is a global provider of outsourced
drug development and commercialisation services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specializes in the strategic development,
management and analysis of programs that support clinical development
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees.

Further information is available at www.iconplc.com

ICON/ICLR-G

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at
http://www.sec.gov.

View Comments and Join the Discussion!